Group COO Joins the Clinigen Board
News Jul 15, 2013
Clinigen Group plc has announced the appointment of Shaun Edward Chilton (45) to the Board of Directors with effect from 11 July 2013.
Shaun Chilton has been employed by the Group since January 2012 as Chief Operating Officer and is a director of Clinigen CTS Limited and Clinigen CTS Inc., subsidiary companies of Clinigen Group plc.
He will now join the Board of Clinigen Group plc as an Executive Director.
Before joining Clinigen, he was the President within KnowledgePoint360 Group, a global pharmaceutical information and services operation.
He has over 20 years’ commercial, strategic and operational experience in senior leadership positions in product- and service-oriented businesses within the pharmaceutical industry.
He has a proven track record of creating and successfully driving business strategies delivering substantial sales, profit and market share growth in a number of international businesses; driving business transformation / change programmes and building, developing and coaching highly motivated, professional multidisciplinary teams.
Peter George, Group Chief Executive Officer said, “Since joining the Group in 2012 Shaun Chilton has been instrumental in driving the business forward, particularly in the CTS business which has grown substantially. His operational and strategic experience will be an asset to the Board as we continue to grow the business.”
Shaun holds 607,600 Ordinary Shares of 0.1 pence each in the Company (“Ordinary Shares”), representing 0.74% of the Company’s issued share capital.
He has share options over a further 412,778 Ordinary Shares, representing 0.5% of the Company’s issued share capital.
There is no further information required to be disclosed pursuant to paragraph (g) of Schedule 2 of the AIM Rules.
Targeted Drug Could be Used to Treat Advanced Cancers Located Anywhere in the BodyNews
A new targeted drug could be used to treat a small number of advanced cancers no matter where they grow in the body.READ MORE
Human Malaria Parasites Grown for the First Time in Dormant FormNews
One of the biggest obstacles to eradicating malaria is a dormant form of the parasite which is resistant to most antimalarial drugs and can reawaken years later, causing disease relapse. Researchers have shown they can grow the dormant parasite in engineered human liver tissue for several weeks, allowing them to closely study how the parasite becomes dormant, what vulnerabilities it may have, and how it springs back to life.READ MORE
Bacteria Produce More Substances Than Genetics PredictedNews
Tandem mass spectrometry has revealed that Streptomyces chartreusis, an antibiotic-producing bacterium, releases more metabolites into the surrounding medium than scientists assumed based on the analysis of the genome. They might include molecules that are of interest as potential pharmaceutical agents.READ MORE